Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Lovenox Petition Offers Premarin Defense To Hold Off Generics

Executive Summary

Aventis is trying the Premarin defense in an attempt to hold off generic competition to its antithrombotic agent Lovenox

You may also be interested in...



Aventis Lovenox Promotions Challenged By Coagulation Test Maker

A diagnostics company that developed a coagulation test for use with Lovenox alleges Aventis is falsely promoting the antithrombotic as requiring "no routine monitoring" and being "therapeutic from dose one.

Aventis Lovenox Promotions Challenged By Coagulation Test Maker

A diagnostics company that developed a coagulation test for use with Lovenox alleges Aventis is falsely promoting the antithrombotic as requiring "no routine monitoring" and being "therapeutic from dose one.

Aventis Lovenox Patent Defense: Re-Issuance Higher Priority Than Stay

Aventis' Lovenox generic defense remains centered on the re-issuance of an enoxaparin patent as the company defends the original version against potential generic competition

Related Content

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel